(IN BRIEF) The GEMINI study, the largest of its kind, has revealed significant genetic overlaps in 72 long-term health conditions related to aging. Conducted by the University of Exeter Medical School and funded by the Medical Research Council and the … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, News, Science, Technology, United Kingdom
Tagged aging, B12 deficiency, BAAINBw, disease overlaps, Dr. Joao Delgado, eBioMedicine, GEMINI study, genetic analysis, genetic factors, genetic overlaps, health research, healthcare services, iron deficiency anaemia, long-term health conditions, Medical Research Council, multimorbidity, multimorbidity prevention, National Institute for Health Research, NIHR, patient records, Personalized Treatment, prevention, primary care, Professor Jane Masoli, treatment, University of Exeter Medical School
(IN BRIEF) The European Economic and Social Committee (EESC) has called for a comprehensive European Action Plan on Rare Diseases by 2030, urging the EU and Member States to enhance cooperation and ensure equal access to diagnosis and treatment. At … Read the full press release
Posted in Belgium, Business, Environment, Financial, Government, Healthcare, Industrial, Investment, Law, Management, News, Politics
Tagged Ágnes Cser, Baiba Miltoviča, diagnosis, EESC, European Action Plan, health, Mónica García Gómez, rare diseases, sustainability, Tomislav Sokol, treatment, wellness
(IN BRIEF) The European Medicines Agency has approved Dupixent as the first treatment for eosinophilic esophagitis (EoE) in young children aged one to 11, marking a significant step in managing this condition in a critical developmental phase. The approval is … Read the full press release
Posted in Business, Education, European Union, Financial, France, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged Dr. George Yancopoulos, Dr. Houman Ashrafian, Dupixent, eosinophilic esophagitis, EU, European Medicines Agency (EMA), Healthcare, Regeneron, safety, Sanofi, treatment, wellness, Young Children
(IN BRIEF) Ultomiris (ravulizumab-cwvz) has gained approval from the FDA as the inaugural long-acting C5 complement inhibitor for treating adult patients with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD). The approval, based on the CHAMPION-NMOSD Phase III trial’s … Read the full press release
Posted in Business, Environment, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged Adrian Kemp, AQP4 Ab+, AstraZeneca, Marc Dunoyer, neuromyelitis optica spectrum disorder (NMOSD), safety, Sean J. Pittock, treatment, Ultomiris, USFDA
(IN BRIEF) Boehringer Ingelheim and Sosei Group Corporation (Sosei Heptares) have unveiled a global collaboration and exclusive option-to-license agreement aimed at advancing the development and commercialization of Sosei Heptares’ portfolio of first-in-class GPR52 agonists. The focus of this collaboration lies … Read the full press release
Posted in Business, Education, Environment, Financial, Germany, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged Boehringer Ingelheim, GPR52 agonists, Hugh Marston, Matt Barnes, mental health, partnership, schizophrenia, Sosei Heptares, sustainability, treatment
(IN BRIEF) Voydeya (danicopan), a first-in-class oral Factor D inhibitor, has been recommended for marketing authorization in the European Union (EU) as an add-on to ravulizumab or eculizumab for adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who experience residual haemolytic … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged Adrian Kemp, AstraZeneca, eculizumab, Marc Dunoyer, PNH, Professor Hubert Schrezenmeier, ravulizumab, safety, treatment, Voydeya
(IN BRIEF) GSK plc has announced positive headline results from the pivotal EAGLE-1 phase III trial for gepotidacin, an oral antibiotic aimed at treating uncomplicated urogenital gonorrhoea in adolescents and adults. The trial demonstrated gepotidacin’s non-inferiority compared to the current … Read the full press release
(IN BRIEF) Boehringer Ingelheim has reported compelling results from its Phase II trial of Survodutide, a novel glucagon/GLP-1 receptor dual agonist, indicating its potential to become a leading treatment for Metabolic Dysfunction-Associated Steatohepatitis (MASH). In the trial, up to 83.0% … Read the full press release
Posted in Business, Education, Financial, Germany, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged Boehringer Ingelheim, Carinne Brouillon, Dr. Arun Sanyal, MASH, Phase II Trial, Survodutide, treatment
(IN BRIEF) In a Phase III trial conducted in Japan, acoramidis, an investigational treatment for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), demonstrated promising high-level results consistent with the global BridgeBio Pharma, Inc. ATTRibute-CM Phase III trial. The trial in Japan aimed to … Read the full press release
Posted in Business, Education, Financial, Germany, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Acoramidis, AstraZeneca, Japan, Marc Dunoyer, Professor Yukio Ando, Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM), treatment
(IN BRIEF) A groundbreaking trial called GUSTO, led jointly by the University of Southampton, Sheffield Teaching Hospitals NHS Foundation Trust, and the University of Leeds, has been launched to potentially revolutionize bladder cancer treatment by matching therapies to the genetic … Read the full press release
Posted in Business, Education, Environment, Financial, Healthcare, Industrial, Investment, Management, News, Science, United Kingdom
Tagged bladder cancer, GUSTO, James Catto, partnership, Sheffield Teaching Hospitals NHS Foundation Trust, Simon Crabb, sustainability, treatment, University of Leeds, University of Southampton
(IN BRIEF) Researchers at the University of Leicester have developed a groundbreaking treatment for severe asthma using the monoclonal antibody tezepelumab. This monthly injection targets thymic stromal lymphopoietin (TSLP), a substance associated with inflammation in the airways of severe asthma … Read the full press release
(IN BRIEF) ViiV Healthcare has received approval from China’s National Medical Products Administration (NMPA) for Vocabria (cabotegravir) in combination with Rekambys (rilpivirine), marking the first complete long-acting HIV-1 injectable treatment in China. This approval allows people living with HIV in … Read the full press release
Posted in Business, Environment, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged cabotegravir, CHINA, Chinese Approval, Deborah Waterhouse, GSK, HIV, injection, partnership, Pfizer, Rekambys, rilpivirine, Shionogi, sustainability, treatment, ViiV Healthcare, Vocabria
(IN BRIEF) ViiV Healthcare, a global specialist HIV company, will present 23 abstracts at the 19th Annual European AIDS Conference (EACS 2023). These abstracts will cover various aspects of HIV treatment and prevention, including real-world data on long-acting and 2-drug … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, Media, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Apretude, Dovato, EACS 2023, GSK, HIV, Kimberly Smith, partnership, Pfizer, prevention, Rekambys, Rukobia, Shionogi, treatment, ViiV Healthcare, Vocabria
(IN BRIEF) GSK has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for the approval of Jemperli (dostarlimab) in combination with chemotherapy as a frontline treatment for adult … Read the full press release
Posted in Business, Education, Healthcare, Industrial, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged chemotherapy, CHMP, dostarlimab, endometrial cancer, GSK, Hesham Abdullah, Jemperli, RUBY, treatment
(IN BRIEF) Alexion, a subsidiary of AstraZeneca Rare Disease, is set to present new data at the 9th Joint Meeting of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple … Read the full press release
Posted in Business, Education, Healthcare, Industrial, Management, Media, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Alexion, Alize Vives, Anna Francis, AQP4, AstraZeneca, Christophe Hotermans, ECTRIMS-ACTRIMS Meeting, effectiveness, Jin Nakahara, Justin Lee, Michael Levy, multiple sclerosis, NMOSD, Rare Neurological Disorder, rituximab, Sami Fam, Soliris, treatment, Ultomiris, Viktoria Papp
(IN BRIEF) Roche has announced positive late-breaking data from the Phase III OCARINA II study, which demonstrates the effectiveness of OCREVUS as a twice-yearly, 10-minute subcutaneous injection for patients with relapsing or primary progressive multiple sclerosis (RMS or PPMS). The … Read the full press release
(IN BRIEF) Merck has presented new data on evobrutinib, an investigational BTK inhibitor, at the 9th Joint ECTRIMS-ACTRIMS congress. The data from an ongoing Phase II open-label extension study of evobrutinib in patients with relapsing multiple sclerosis (RMS) show sustained … Read the full press release
Posted in Business, Education, Germany, Healthcare, Industrial, Management, News, Pharma & Biotech, Science
Tagged BTKi, Evobrutinib, Jan Klatt, Merck, multiple sclerosis, relapsing multiple sclerosis (RMS), treatment
(IN BRIEF) The Japanese Ministry of Health, Labor, and Welfare (MHLW) has granted marketing authorization for ALTUVIIIO, a novel factor VIII replacement therapy used to control bleeding in patients with hemophilia A. ALTUVIIIO, also known as efanesoctocog alfa, stands out … Read the full press release
Posted in Business, Financial, France, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science
Tagged ALTUVIIIO, authorization, bleeding, Brian Foard, efanesoctocog alfa, FDA, hemophilia A, Japan, marketing, MHLW, partnership, Sanofi, Sobi, treatment
(IN BRIEF) A study conducted by the University of York, in collaboration with ieso Digital Health Ltd and Dorset HealthCare University NHS Trust, has found that internet-delivered cognitive behavioral therapy (CBT) offers greater cost-effectiveness and comparable clinical effectiveness compared to … Read the full press release
Posted in Business, Education, Financial, Healthcare, Internet & Online, Management, News, Science, United Kingdom
Tagged anxiety, Cognitive Behavioral Therapy, Cost-Effective Alternative, depression, Dorset HealthCare University NHS Trust, ieso Digital Health Ltd, Internet-Delivered, mental health, partnership, Sam Harper, treatment, University of York
(IN BRIEF) The Paul Scherrer Institute (PSI) has administered proton radiotherapy to a 67-year-old patient with oesophageal cancer, marking the first time this treatment has been used in Switzerland for such a case. The treatment is part of a collaborative … Read the full press release
Posted in Business, Healthcare, Industrial, Management, News, Science, Switzerland, Technology
Tagged clinical trial, Damien Weber, Dominic Leiser, Matthias Guckenberger, Oesophageal Cancer, Panagiotis Balermpas, Paul Scherrer Institute, PROTECT (PROton versus photon Therapy for Esophageal Cancer: a Trimodality Strategy), Proton Radiotherapy, Switzerland, treatment, University Hospital Zurich, wellness
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?